MART-1 / Melan-A Antibody for IHC, 20ug

Melan A (MLANA), also known as melanoma antigen recognized by T cells 1, is a melanocyte differentiation protein that plays a key role in melanosome biogenesis and pigment production. It is selectively expressed in normal melanocytes and the majority of melanocytic tumors, making it one of the most widely used lineage-specific markers in diagnostic and research immunohistochemistry. In FFPE tissues, Melan A is detected as cytoplasmic HRP-DAB brown staining within melanocytes and melanoma cells, providing a distinct and interpretable pattern for identifying melanocytic differentiation. Melan A Antibody for IHC is therefore extensively used to evaluate melanocytic lesions and distinguish melanoma from morphologically similar non-melanocytic tumors.<br><br>Melan A antibody, also referred to as MLANA antibody or MART-1 antibody in the literature, recognizes a cytoplasmic protein with highly restricted expression in melanocytic cells. This Melan A Antibody for IHC is optimized for Tissue Microarray (TMA)-based immunohistochemistry, enabling high-throughput, standardized comparison of melanocytic marker expression across large panels of normal and cancer tissues. In normal tissue TMAs, staining is confined to melanocytes within the epidermis and related structures, while the vast majority of non-melanocytic tissues remain negative, producing a clean background that enhances specificity and interpretability.<br><br>In cancer tissue microarrays, Melan A expression is strongly and consistently observed in melanoma, where diffuse cytoplasmic staining highlights tumor cells of melanocytic origin. This pattern enables clear distinction between melanoma and carcinomas, sarcomas, and other non-melanocytic malignancies, as surrounding stromal and epithelial components remain negative. The ability to visualize melanocytic tumor cells with high contrast across TMA cores supports its use in comparative tumor profiling and lineage determination studies.<br><br>Tissue Microarray (TMA) analysis enables side-by-side evaluation of MLANA expression across hundreds of tissue cores under identical staining conditions, demonstrating highly reproducible staining in melanocytic tissues alongside minimal background in unrelated cell types. Clone MSVA-901M+ produces strong, well-defined cytoplasmic staining across TMA panels, supporting its use in large-scale immunohistochemistry studies and melanoma research. Observed staining patterns align with established MLANA biology and reference datasets such as the Human Protein Atlas.<br><br>This antibody targets Melan A in research applications requiring precise and interpretable immunohistochemical detection of melanocytic lineage markers, making it well suited for studies of melanoma, melanocyte biology, and tumor classification.<br><br>This antibody is part of the <a href=../melan-a-antibody.html>Melan-A antibody collection</a>, where additional MLANA/MART-1 antibodies for various applications can be explored.<br><br>This antibody is also part of a broader collection of <a href='/ihc-antibodies-tissue-microarray-validated.html'>IHC antibodies validated by tissue microarray analysis</a>, supporting consistent staining across normal and cancer tissues.

Specifications